BioWorld

Oct. 8, 2009

MannKind Bulls, Bears Face off in Wake of Afresa Partner Delay

News that MannKind Corp. will not achieve its goal of signing a partnership this year for inhaled insulin product Afresa polarized the company's bullish backers and its bearish detractors. (BioWorld Today) Read More

Epizyme's $32M to Fuel HMTs; Nobel Winner Helps the Push

Androxal Gives Repros Relief; Proellex, Cash Troubles Loom

Allos Expands Offering, Adds $100M for Folotyn Launch Prep

MIT Biochemist, Stem-Cell Ace Among National Medal Winners

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 22, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.